Emerging bronchoscopic treatments for chronic obstructive pulmonary disease

Wouter H. van Geffen; Huib A. M. Kerstjens; Dirk-Jan Slebos

doi:10.1016/j.pharmthera.2017.05.007

Emerging bronchoscopic treatments for chronic obstructive pulmonary disease

Wouter H. van Geffen^*, Huib A. M. Kerstjens, Dirk-Jan Slebos

^*Corresponding author voor dit werk

Groningen Research Institute for Asthma and COPD

Onderzoeksoutput: Review article › peer review

25 Citaten (Scopus)

366 Downloads (Pure)

Samenvatting

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by pathophysiological factors including airflow limitation, hyperinflation and reduced gas exchange. Treatment consists of lifestyle changes, lung rehabilitation and pharmacological therapies such as long acting beta-2-agonists (LABA) and long acting muscarinic antagonists (LAMA). More recently bronchoscopic treatments are emerging for COPD. Among them endobronchial valves (EBV) and endobronchial coils (EBC), next to endobronchial stents, sclerosing agents, targeted lung denervation and liquid nitrogen metered cryospray. In this review we aim to summarize the new emerging bronchoscopic treatments and their effect sizes compared with lung rehabilitation and pharmacological therapies.

Originele taal-2	English
Pagina's (van-tot)	96-101
Aantal pagina's	6
Tijdschrift	Pharmacology & Therapeutics
Volume	179
DOI's	https://doi.org/10.1016/j.pharmthera.2017.05.007
Status	Published - nov.-2017

Toegang tot document

10.1016/j.pharmthera.2017.05.007Licentie: CC BY

Emerging bronchoscopic treatments for chronic obstructive pulmonary diseaseFinal publisher's version, 361 KBLicentie: CC BY

Handle.net

Permanente koppeling

Citeer dit

@article{622b39d709e84ada94ddcae4cf25b4dd,

title = "Emerging bronchoscopic treatments for chronic obstructive pulmonary disease",

abstract = "Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by pathophysiological factors including airflow limitation, hyperinflation and reduced gas exchange. Treatment consists of lifestyle changes, lung rehabilitation and pharmacological therapies such as long acting beta-2-agonists (LABA) and long acting muscarinic antagonists (LAMA). More recently bronchoscopic treatments are emerging for COPD. Among them endobronchial valves (EBV) and endobronchial coils (EBC), next to endobronchial stents, sclerosing agents, targeted lung denervation and liquid nitrogen metered cryospray. In this review we aim to summarize the new emerging bronchoscopic treatments and their effect sizes compared with lung rehabilitation and pharmacological therapies.",

keywords = "Chronic obstructive pulmonary disease (COPD), Hyperinflation, Endobronchial valves (EBV), Endobronchial coils (EBC), Lung volume reduction, Bronchoscopic treatment, LUNG-VOLUME-REDUCTION, RANDOMIZED CONTROLLED-TRIAL, SEVERE-EMPHYSEMA, ENDOBRONCHIAL VALVES, MEDICAL THERAPY, GAS-EXCHANGE, COPD, MULTICENTER, SURGERY, HYPERINFLATION",

author = "\{van Geffen\}, \{Wouter H.\} and Kerstjens, \{Huib A. M.\} and Dirk-Jan Slebos",

year = "2017",

month = nov,

doi = "10.1016/j.pharmthera.2017.05.007",

language = "English",

volume = "179",

pages = "96--101",

journal = "Pharmacology \& Therapeutics",

issn = "0163-7258",

publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

}

TY - JOUR

T1 - Emerging bronchoscopic treatments for chronic obstructive pulmonary disease

AU - van Geffen, Wouter H.

AU - Kerstjens, Huib A. M.

AU - Slebos, Dirk-Jan

PY - 2017/11

Y1 - 2017/11

N2 - Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by pathophysiological factors including airflow limitation, hyperinflation and reduced gas exchange. Treatment consists of lifestyle changes, lung rehabilitation and pharmacological therapies such as long acting beta-2-agonists (LABA) and long acting muscarinic antagonists (LAMA). More recently bronchoscopic treatments are emerging for COPD. Among them endobronchial valves (EBV) and endobronchial coils (EBC), next to endobronchial stents, sclerosing agents, targeted lung denervation and liquid nitrogen metered cryospray. In this review we aim to summarize the new emerging bronchoscopic treatments and their effect sizes compared with lung rehabilitation and pharmacological therapies.

AB - Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by pathophysiological factors including airflow limitation, hyperinflation and reduced gas exchange. Treatment consists of lifestyle changes, lung rehabilitation and pharmacological therapies such as long acting beta-2-agonists (LABA) and long acting muscarinic antagonists (LAMA). More recently bronchoscopic treatments are emerging for COPD. Among them endobronchial valves (EBV) and endobronchial coils (EBC), next to endobronchial stents, sclerosing agents, targeted lung denervation and liquid nitrogen metered cryospray. In this review we aim to summarize the new emerging bronchoscopic treatments and their effect sizes compared with lung rehabilitation and pharmacological therapies.

KW - Chronic obstructive pulmonary disease (COPD)

KW - Hyperinflation

KW - Endobronchial valves (EBV)

KW - Endobronchial coils (EBC)

KW - Lung volume reduction

KW - Bronchoscopic treatment

KW - LUNG-VOLUME-REDUCTION

KW - RANDOMIZED CONTROLLED-TRIAL

KW - SEVERE-EMPHYSEMA

KW - ENDOBRONCHIAL VALVES

KW - MEDICAL THERAPY

KW - GAS-EXCHANGE

KW - COPD

KW - MULTICENTER

KW - SURGERY

KW - HYPERINFLATION

U2 - 10.1016/j.pharmthera.2017.05.007

DO - 10.1016/j.pharmthera.2017.05.007

M3 - Review article

C2 - 28527920

SN - 0163-7258

VL - 179

SP - 96

EP - 101

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

ER -

Emerging bronchoscopic treatments for chronic obstructive pulmonary disease

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit